Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Sees Significant Decrease in Short Interest

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 400 shares, a decline of 96.9% from the August 15th total of 12,900 shares. Based on an average daily trading volume, of 154,300 shares, the short-interest ratio is presently 0.0 days.

Chugai Pharmaceutical Price Performance

OTCMKTS:CHGCY traded up $1.02 on Thursday, hitting $24.12. 87,323 shares of the company’s stock were exchanged, compared to its average volume of 117,336. The company has a market cap of $79.35 billion, a P/E ratio of 33.97 and a beta of 0.89. The firm has a 50-day moving average price of $21.66 and a 200-day moving average price of $18.88. Chugai Pharmaceutical has a 52 week low of $13.85 and a 52 week high of $25.99.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.22 EPS for the quarter. The firm had revenue of $2.03 billion during the quarter. Chugai Pharmaceutical had a return on equity of 21.45% and a net margin of 32.68%. On average, research analysts expect that Chugai Pharmaceutical will post 0.78 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.